Solventum (NYSE:SOLV) Releases Earnings Results, Beats Expectations By $0.13 EPS

Key Points

• Beat expectations: Solventum reported Q1 EPS of $1.48, beating the $1.35 consensus by $0.13 and delivering revenue of $2.01B versus the $1.97B estimate, and the company set FY2026 EPS guidance at 6.600.
• The stock traded up to $69.09 on the news with above‑average volume; Solventum has a market cap of about $11.98B and trades at a low P/E of 7.79 (1‑year range $62.38–$88.20).
• An insider (Director Amy McBride Wendell) purchased 1,475 shares, increasing her stake by 41.4%, while analysts remain mixed—consensus rating "Hold" with an average price target of $89.45 (7 Buys, 5 Holds, 1 Sell).

Solventum (NYSE:SOLV - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.35 by $0.13, FiscalAI reports. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The firm had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Solventum updated its FY 2026 guidance to 6.600-6.600 EPS.

Solventum Price Performance

Shares of NYSE:SOLV traded up $1.65 during mid-day trading on Tuesday, reaching $69.09. The stock had a trading volume of 1,942,876 shares, compared to its average volume of 1,217,466. The business's 50 day moving average price is $67.99 and its 200 day moving average price is $74.53. Solventum has a 1 year low of $62.38 and a 1 year high of $88.20. The company has a market cap of $11.98 billion, a P/E ratio of 7.79, a price-to-earnings-growth ratio of 1.09 and a beta of 0.59. The company has a current ratio of 1.23, a quick ratio of 0.89 and a debt-to-equity ratio of 1.00.

Insiders Place Their Bets

In other news, Director Amy Mcbride Wendell acquired 1,475 shares of Solventum stock in a transaction on Tuesday, March 10th. The shares were acquired at an average price of $68.03 per share, with a total value of $100,344.25. Following the purchase, the director directly owned 5,039 shares in the company, valued at $342,803.17. The trade was a 41.39% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.24% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. BOKF NA increased its position in Solventum by 6.9% in the third quarter. BOKF NA now owns 2,193 shares of the company's stock worth $160,000 after purchasing an additional 141 shares during the last quarter. Smartleaf Asset Management LLC lifted its position in Solventum by 23.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 744 shares of the company's stock valued at $60,000 after purchasing an additional 142 shares during the last quarter. Lazard Asset Management LLC grew its stake in shares of Solventum by 1.4% in the 2nd quarter. Lazard Asset Management LLC now owns 11,605 shares of the company's stock worth $880,000 after buying an additional 163 shares in the last quarter. Orion Porfolio Solutions LLC grew its stake in shares of Solventum by 0.7% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 24,295 shares of the company's stock worth $1,843,000 after buying an additional 176 shares in the last quarter. Finally, Lido Advisors LLC increased its holdings in shares of Solventum by 2.3% in the 4th quarter. Lido Advisors LLC now owns 7,899 shares of the company's stock worth $583,000 after buying an additional 178 shares during the last quarter.

Analyst Ratings Changes

SOLV has been the subject of several recent analyst reports. Stifel Nicolaus upped their target price on shares of Solventum from $88.00 to $105.00 and gave the stock a "buy" rating in a report on Wednesday, January 7th. Weiss Ratings restated a "hold (c)" rating on shares of Solventum in a research report on Tuesday, January 27th. Wall Street Zen lowered Solventum from a "buy" rating to a "hold" rating in a research note on Sunday, March 8th. Piper Sandler cut their target price on Solventum from $98.00 to $92.00 and set an "overweight" rating for the company in a research report on Friday, April 17th. Finally, BTIG Research reissued a "buy" rating and set a $100.00 target price on shares of Solventum in a research note on Friday, February 27th. Seven equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $89.45.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.